Vaccine compositions and methods of making same
AssigneeTNG Pharmaceuticals, Inc.
InventorsKent R. Van Kampen, Serge Martinod
Life of this patent
Estimating the term…
Abstract
Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.
Claims20
A fusion protein comprising
- a. a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein said thrombostasin protein comprises a carboxy terminal deletion;
- and
- b. a fusion partner protein comprising a non-thrombostasin protein component.
A vaccine composition comprising a thrombostasin sequence having a comprising a carboxy terminal deletion, wherein said deletion is the last 35 amino acids, the last 34 amino acids, the last 33 amino acids, the last 32 amino acids, the last 31 amino acids, the last 30 amino acids, the last 29 amino acids, the last 28 amino acids, the last 27 amino acids, the last 26 amino acids, the last 25 amino acids, the last 24 amino acids, the last 23 amino acids, the last 22 amino acids, the last 21 amino acids, or the last 20 amino acids.
A method for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising administering a therapeutically effective amount of a composition comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein said thrombostasin protein comprises a carboxy terminal deletion to said host.
A method for preparation of a fusion protein composition, comprising
- a. generating a plasmid for expressing a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein said thrombostasin protein comprises a carboxy terminal deletion;
- b. causing the plasmid to express said fusion protein within a host cell;
- and
- c. collecting the fusion protein from said host cell.
Dependencies are inferred from the claim text.